Buy One Get One free -Llimited Time Offer X
Dilvas 2.5 Tablet, a prescription drug, is manufactured in various forms such as Tablet. It is typically used for the treatment of High BP. Dilvas 2.5 Tablet also has some secondary and off-label uses. These are listed below.
Medical history of the patient along with age and gender determines the dosage of Dilvas 2.5 Tablet. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
Apart from the aforementioned side effects, Dilvas 2.5 Tablet can also lead to other problems, which have been listed below. Usually, these side effects of Dilvas 2.5 Tablet go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Dilvas 2.5 Tablet is Severe for pregnant women and Severe for women who are breastfeeding. Warnings related to Dilvas 2.5 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Individuals suffering from medical conditions like Angioedema, Low Blood Pressure (Hypotension) must refrain from the use of Dilvas 2.5 Tablet since this can cause severe adverse effects. The section on Dilvas 2.5 Tablet contraindications lists all such conditions.
Drug interactions for Dilvas 2.5 Tablet have been reported in the medical literature. A complete list of these interactions is given below.
You should also be aware that Dilvas 2.5 Tablet is not safe while driving, and is not addiction.
Dilvas 2.5 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
2 - 12 years (Child) |
|
13 - 18 years (Adolescent) |
|
Is the use of Dilvas 2.5 Tablet safe for pregnant women?
Dilvas can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Dilvas 2.5 Tablet safe during breastfeeding?
Dilvas may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Dilvas 2.5 Tablet on the Kidneys?
Very few cases of side effects of Dilvas on kidney have been reported.
What is the effect of Dilvas 2.5 Tablet on the Liver?
Dilvas is rarely harmful for the liver.
What is the effect of Dilvas 2.5 Tablet on the Heart?
Very few cases of side effects of Dilvas on the heart have been reported.
If you are suffering from any of the following diseases, you should not take Dilvas 2.5 Tablet unless your doctor advises you to do so -
Is this Dilvas 2.5 Tablet habit forming or addictive?
Forming a habit of Dilvas 2.5 Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
After taking Dilvas 2.5 Tablet, you should not drive or work on any heavy machine, as Dilvas 2.5 Tablet can make you drowsy.
Is it safe?
Yes, but take Dilvas 2.5 Tablet only as per medical advice.
Is it able to treat mental disorders?
No, the use of Dilvas 2.5 Tablet in mental disorders is not effective.
Interaction between Food and Dilvas 2.5 Tablet
When consumed with certain foods, Dilvas 2.5 Tablet may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Dilvas 2.5 Tablet
It is difficult to say anything about the effect of Dilvas 2.5 Tablet and alcohol. No research has been done on this yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Epaned (enalapril maleate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 502-503